Theranexus, a biopharmaceutical company specializing in rare neurological diseases, announces the appointment of Mathieu Charvériat as Chairman of the Board of Directors, in addition to his current duties as CEO.

This appointment takes effect on March 31, following the resignation of Franck Mouthon, who becomes Executive Director of the Agence de programmes pour la recherche en santé, while remaining a director within Theranexus.

Copyright (c) 2024 CercleFinance.com. All rights reserved.